| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.0082 | 0.8 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.8 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.9 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.9 |